RxDoctor Payments Data

Rajesh Subramanian

Interventional Cardiology · Everett, WANPI 1265419741

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 24 payments — averaging $55.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$360
  • GE HealthCare$193
  • Heartflow, Inc.$133
  • Philips North America LLC$113
  • W. L. Gore & Associates, Inc.$111
  • Cleerly, Inc.$70
  • plus $343 from 8 others

What the payments were for

  • Food & beverage$1,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,324 in reported general payments places this provider in the 25th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$209,224
Medicare patients
822
Services billed
2,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin281$312,577
EliquisApixaban189$238,473
EntrestoSacubitril/Valsartan29$48,916
XareltoRivaroxaban30$38,760
Metoprolol Succinate791$10,686
Atorvastatin Calcium426$6,819
Potassium Chloride117$3,353
Rosuvastatin Calcium271$3,324
Losartan Potassium297$2,915
Amlodipine Besylate343$2,422
Cilostazol74$2,379
ClopidogrelClopidogrel Bisulfate174$2,311
Ezetimibe78$1,961
Spironolactone209$1,886
Valsartan17$1,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$31$48,91629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →